S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
CNSX:BOLT

Bolt Biotherapeutics Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume71,500 shs
Average Volume18,200 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive BOLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Bolt Biotherapeutics

Bolt Metals Corp., an exploration company, focuses on the acquisition and development of cobalt projects for lithium-ion battery industry. Its principal asset is the Cyclops nickel-cobalt project that covers an area of 5,000 hectors with 9 prospects located in Indonesia. The company was formerly known as Pacific Rim Cobalt Corp. and changed its name to Bolt Metals Corp. in February 2020. Bolt Metals Corp. is headquartered in West Vancouver, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Industrial Metals & Minerals
Sub-Industry
N/A
CIK
N/A
Employees
65
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.99 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Bolt Biotherapeutics (CNSX:BOLT) Frequently Asked Questions

What stocks does MarketBeat like better than Bolt Biotherapeutics?

Wall Street analysts have given Bolt Biotherapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bolt Biotherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Bolt Biotherapeutics' key executives?

Bolt Biotherapeutics' management team includes the following people:
  • Mr. Ranjeet Sundher, Pres, CEO & Director (Age 55, Pay $204.14k)
  • Mr. Steven Edward Vanry C.F.A., CFA, CIM, CFO, Sec. & Director
  • Mr. Alwi Nabil, Country Financial Controller

What other stocks do shareholders of Bolt Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Intelsat (I), Associated British Foods (ABF), Chaarat Gold (CGH), Fossil Group (FOSL), AMC Entertainment (AMC), Bank of America (BAC), First Data (FDC), Air Canada (AC), Apollo Global Management (APO) and China Unicom (Hong Kong) (CHU).

What is Bolt Biotherapeutics' stock symbol?

Bolt Biotherapeutics trades on the CNSX under the ticker symbol "BOLT."

How many employees does Bolt Biotherapeutics have?

Bolt Biotherapeutics employs 65 workers across the globe.

What is Bolt Biotherapeutics' official website?

The official website for Bolt Biotherapeutics is pacificrimcobalt.com.

Where are Bolt Biotherapeutics' headquarters?

Bolt Biotherapeutics is headquartered at 640 Galveston Drive, Redwood City, California 94063.

How can I contact Bolt Biotherapeutics?

Bolt Biotherapeutics' mailing address is 640 Galveston Drive, Redwood City, California 94063. The company can be reached via phone at 604-922-8272.


This page was last updated on 10/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.